Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd. committed to technology innovations and providing a total solution from “Idea to IND” (“I to ITM”), has entered into a collaboration agreement with Boostimmune, a biotech company developing next-generation anti-cancer therapies via modulating immune systems. The collaboration aims to leverage Nona’s Harbour Mice H2L2 (two light and two heavy chain) platform to accelerate the development of Antibody-Drug Conjugates (ADCs) against novel targets.
 
Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, said, “By leveraging our accumulated knowledge of ADC discovery and utilizing our advanced therapeutic antibody platforms validated by partners worldwide, this collaboration will expedite the development of first-in-class ADCs targeting cancer. Working alongside Boostimmune, we anticipate delivering transformative treatments, ultimately improving outcomes for all patients affected by cancer.”
 
Gwanghee Lee, Founder and CEO of Boostimmune, said, “We are excited to collaborate with Nona Biosciences. Our strategic alignment of resources and knowledge will accelerate the development of ADC therapies against novel targets. Through this collaboration, we are confident in making significant strides in addressing the unmet needs of cancer patients.”